RVMD Annual EBITDA
-$430.28 M
-$190.81 M-79.68%
31 December 2023
Summary:
As of January 22, 2025, RVMD annual earnings before interest, taxes, depreciation & amortization is -$430.28 million, with the most recent change of -$190.81 million (-79.68%) on December 31, 2023. During the last 3 years, it has fallen by -$328.37 million (-322.20%). RVMD annual EBITDA is now -1342.15% below its all-time high of -$29.84 million, reached on December 31, 2017.RVMD EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RVMD Quarterly EBITDA
-$172.84 M
-$18.99 M-12.34%
30 September 2024
Summary:
As of January 22, 2025, RVMD quarterly earnings before interest, taxes, depreciation & amortization is -$172.84 million, with the most recent change of -$18.99 million (-12.34%) on September 30, 2024. Over the past year, it has dropped by -$34.74 million (-25.16%). RVMD quarterly EBITDA is now -1762.45% below its all-time high of -$9.28 million, reached on June 30, 2019.RVMD Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RVMD TTM EBITDA
-$594.30 M
-$51.73 M-9.53%
30 September 2024
Summary:
As of January 22, 2025, RVMD TTM earnings before interest, taxes, depreciation & amortization is -$594.30 million, with the most recent change of -$51.73 million (-9.53%) on September 30, 2024. Over the past year, it has dropped by -$98.55 million (-19.88%). RVMD TTM EBITDA is now -5498.73% below its all-time high of -$10.62 million, reached on December 31, 2018.RVMD TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RVMD EBITDA Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -79.7% | -25.2% | -19.9% |
3 y3 years | -322.2% | -237.6% | -268.5% |
5 y5 years | -978.1% | -438.0% | -483.1% |
RVMD EBITDA High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -139.4% | at low | -246.0% | at low | -230.6% | at low |
5 y | 5-year | -785.5% | at low | -855.9% | at low | -1123.1% | at low |
alltime | all time | -1342.2% | at low | -1762.5% | at low | -5498.7% | at low |
Revolution Medicines EBITDA History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sept 2024 | - | -$172.84 M(+12.3%) | -$594.30 M(+9.5%) |
June 2024 | - | -$153.85 M(+11.4%) | -$542.57 M(+9.4%) |
Mar 2024 | - | -$138.10 M(+6.6%) | -$495.75 M(+15.2%) |
Dec 2023 | -$430.28 M(+79.7%) | -$129.53 M(+7.0%) | -$430.28 M(+22.7%) |
Sept 2023 | - | -$121.10 M(+13.2%) | -$350.70 M(+15.5%) |
June 2023 | - | -$107.02 M(+47.4%) | -$303.70 M(+18.4%) |
Mar 2023 | - | -$72.62 M(+45.4%) | -$256.43 M(+7.1%) |
Dec 2022 | -$239.47 M(+33.2%) | -$49.95 M(-32.6%) | -$239.47 M(-0.3%) |
Sept 2022 | - | -$74.10 M(+24.0%) | -$240.13 M(+10.5%) |
June 2022 | - | -$59.76 M(+7.4%) | -$217.22 M(+8.7%) |
Mar 2022 | - | -$55.66 M(+10.0%) | -$199.92 M(+11.2%) |
Dec 2021 | -$179.75 M | -$50.61 M(-1.1%) | -$179.75 M(+11.5%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sept 2021 | - | -$51.19 M(+20.6%) | -$161.26 M(+18.9%) |
June 2021 | - | -$42.46 M(+19.6%) | -$135.65 M(+14.2%) |
Mar 2021 | - | -$35.49 M(+10.5%) | -$118.77 M(+16.5%) |
Dec 2020 | -$101.91 M(+109.7%) | -$32.13 M(+25.6%) | -$101.91 M(+16.0%) |
Sept 2020 | - | -$25.57 M(-0.0%) | -$87.87 M(+18.4%) |
June 2020 | - | -$25.58 M(+37.3%) | -$74.21 M(+28.2%) |
Mar 2020 | - | -$18.63 M(+3.0%) | -$57.91 M(+19.2%) |
Dec 2019 | -$48.59 M(+21.7%) | -$18.08 M(+51.7%) | -$48.59 M(+18.2%) |
Sept 2019 | - | -$11.92 M(+28.4%) | -$41.12 M(+40.8%) |
June 2019 | - | -$9.28 M(-0.3%) | -$29.20 M(+46.6%) |
Mar 2019 | - | -$9.31 M(-12.3%) | -$19.92 M(+87.7%) |
Dec 2018 | -$39.91 M(+33.8%) | -$10.62 M | -$10.62 M |
Dec 2017 | -$29.84 M | - | - |
FAQ
- What is Revolution Medicines annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Revolution Medicines?
- What is Revolution Medicines annual EBITDA year-on-year change?
- What is Revolution Medicines quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Revolution Medicines?
- What is Revolution Medicines quarterly EBITDA year-on-year change?
- What is Revolution Medicines TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Revolution Medicines?
- What is Revolution Medicines TTM EBITDA year-on-year change?
What is Revolution Medicines annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of RVMD is -$430.28 M
What is the all time high annual EBITDA for Revolution Medicines?
Revolution Medicines all-time high annual earnings before interest, taxes, depreciation & amortization is -$29.84 M
What is Revolution Medicines annual EBITDA year-on-year change?
Over the past year, RVMD annual earnings before interest, taxes, depreciation & amortization has changed by -$190.81 M (-79.68%)
What is Revolution Medicines quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of RVMD is -$172.84 M
What is the all time high quarterly EBITDA for Revolution Medicines?
Revolution Medicines all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$9.28 M
What is Revolution Medicines quarterly EBITDA year-on-year change?
Over the past year, RVMD quarterly earnings before interest, taxes, depreciation & amortization has changed by -$34.74 M (-25.16%)
What is Revolution Medicines TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of RVMD is -$594.30 M
What is the all time high TTM EBITDA for Revolution Medicines?
Revolution Medicines all-time high TTM earnings before interest, taxes, depreciation & amortization is -$10.62 M
What is Revolution Medicines TTM EBITDA year-on-year change?
Over the past year, RVMD TTM earnings before interest, taxes, depreciation & amortization has changed by -$98.55 M (-19.88%)